News headlines about Gemphire Therapeutics (NASDAQ:GEMP) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.4600004690385 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Gemphire Therapeutics (NASDAQ GEMP) traded up $0.23 on Friday, reaching $8.00. The company had a trading volume of 35,290 shares, compared to its average volume of 24,163. Gemphire Therapeutics has a 52-week low of $7.20 and a 52-week high of $21.59. The company has a quick ratio of 4.17, a current ratio of 4.17 and a debt-to-equity ratio of 1.00.
Gemphire Therapeutics (NASDAQ:GEMP) last posted its earnings results on Monday, November 13th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.14). analysts predict that Gemphire Therapeutics will post -3.31 earnings per share for the current year.
Several brokerages have recently commented on GEMP. Zacks Investment Research cut Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 17th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price (up previously from $21.00) on shares of Gemphire Therapeutics in a research report on Tuesday, November 14th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $22.00 target price on shares of Gemphire Therapeutics in a research report on Friday, October 27th. Canaccord Genuity reissued a “buy” rating and set a $31.00 price objective on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Finally, Roth Capital began coverage on Gemphire Therapeutics in a research report on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Gemphire Therapeutics presently has an average rating of “Buy” and a consensus price target of $22.17.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/10/gemphire-therapeutics-gemp-given-daily-news-impact-rating-of-0-13.html.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.